Hyperion DeFi, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 3.505 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 54.47M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Hyperion DeFi, Inc., a DeFi company, engages in building on Hyperliquid. It operates through two segments: Ophthalmic Technology and Digital Assets. The company focuses on the long-term strategic treasury of HYPE tokens to provide simplified exposure to the Hyperliquid blockchain ecosystem. It is also developing the Optejet User Filled Device to work with various topical ophthalmic liquids, including artificial tears and lens rewetting products. The company was formerly known as Eyenovia, Inc. and changed its name to Hyperion DeFi, Inc. in July 2025. Hyperion DeFi, Inc. was founded in 2014 and is based in Dallas, Texas.
Details
| Name | Hyperion DeFi, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 9 |
| Founded | 2014 |
| Ipo Date | 2018-01-25 |
| Ceo | Hyunsu Jung |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US30234E2037 |
| Cusip | 30234E203 |
| Cik | 1682639 |
| Sic | 6199 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Hyunsu Jung | Chief Executive Officer, Chief Investment Officer and Director |
| David Knox C.F.A. | Chief Financial Officer and Treasurer |
| Robert Rubenstein | General Counsel and Secretary |
| Jason Assad | Investor Contact |
| Alexander Lobo | Investor Contact |
Contact
| Address | 3090 Nowitzki Way, Suite 300, Dallas, Texas 75219, United States |
| Phone | 833 393 6684 |
| Website | https://hyperiondefi.com |